Download PDF
Int J Angiol 2023; 32(04): 284-287
DOI: 10.1055/s-0041-1741470
Case Report

A Renal Artery Stenting Case: Support for Increased Use of Drug-Eluting Stents

Achim Viertel
1   Asklepios Klinik Barmbek-Cardiology, Ruebenkamp 220, Hamburg, Germany
,
Nils Breese
2   Nephrocare Hamburg-Barmbek, Hebebrandstrasse 6, Hamburg, Germany
,
Lars Krist
1   Asklepios Klinik Barmbek-Cardiology, Ruebenkamp 220, Hamburg, Germany
,
Gerian Groenefeld
1   Asklepios Klinik Barmbek-Cardiology, Ruebenkamp 220, Hamburg, Germany
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Fibromuscular dysplasia is a rare, systemic arteriovascular disease that often affects the renal arteries. Balloon angioplasty is recommended for uncontrolled hypertension and compromised renal function; stenting is a bailout option. Drug-eluting stents have been suggested in case reports. We report the successful intervention with an everolimus-coated stent in a very young patient. The patient was followed for 2 years after placing the stent. The success of this case suggests that drug-eluting stents should be used more frequently in comparable situations.

Keywords

renal artery stenosis - fibromuscular dysplasia - duplex ultrasound - percutaneous renal balloon angioplasty - drug-eluting stent - uncontrolled hypertension - antihypertensive therapy


Publication History

Article published online:
05 February 2022

© 2022. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Edem E, Aksoy MN, Pabuccu MT, Tatlı E. Endovascular treatment of renal artery stenosis due to fibromuscular dysplasia—is stent implantation underused in this circumstance?. Heart Views 2016; 17 (02) 69-71
    CrossrefPubMedGoogle Scholar
  • 2 Herrmann SM, Textor SC. Current concepts in the treatment of renovascular hypertension. Am J Hypertens 2018; 31 (02) 139-149
    CrossrefPubMedGoogle Scholar
  • 3 Gornik HL, Persu A, Adlam D. et al. First international consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med 2019; 24 (02) 164-189
    CrossrefPubMedGoogle Scholar
  • 4 Plouin PF, Baguet JP, Thony F. et al; ARCADIA Investigators. High prevalance of multiple arterial bed lesions in patients with fibromuscular dysplasia. The ARCADIA Registry (assessment of renal and cervical artery dysplasia). Hypertension 2017; 70 (03) 652-658
    CrossrefPubMedGoogle Scholar
  • 5 Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ, Lumsden AB. The long-term outcomes of percutaneous therapy for renal artery fibromuscular dysplasia. J Vasc Surg 2008; 48 (04) 865-871
    CrossrefPubMedGoogle Scholar
  • 6 Morosetti D, Chiocchi M, De Crescenzo F. et al. Bilateral renal artery stenosis treated with drug-eluting balloon angioplasty in unique treatment. Radiol Case Rep 2018; 14 (02) 242-245
    CrossrefPubMedGoogle Scholar
  • 7 Farb A, Malone M, Maisel WH. Drug-coated devices for peripheral arterial disease. N Engl J Med 2021; 384 (02) 99-101
    CrossrefPubMedGoogle Scholar
  • 8 Nordanstig J, James S, Andersson M. et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med 2020; 383 (26) 2538-2546
    CrossrefPubMedGoogle Scholar
  • 9 Olin JW, Gornik HL, Bacharach JM. et al; American Heart Association Council on Peripheral Vascular Disease, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, American Heart Association Council on Cardiovascular Disease in the Young, American Heart Association Council on Cardiovascular Radiology and Intervention, American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Functional Genomics and Translational Biology, American Heart Association Council for High Blood Pressure Research, American Heart Association Council on the Kidney in Cardiovascular Disease, American Heart Association Stroke Council. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation 2014; 129 (09) 1048-1078
    CrossrefPubMedGoogle Scholar